Pharming Group Nv Stock Current Valuation
| PHGUF Stock | USD 0.93 0.05 5.68% |
Valuation analysis of Pharming Group NV helps investors to measure Pharming Group's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Pharming Group's price fluctuation is dangerous at this time. Calculation of the real value of Pharming Group NV is based on 3 months time horizon. Increasing Pharming Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pharming pink sheet is determined by what a typical buyer is willing to pay for full or partial control of Pharming Group NV. Since Pharming Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharming Pink Sheet. However, Pharming Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.93 | Real 0.75 | Hype 0.93 | Naive 0.92 |
The real value of Pharming Pink Sheet, also known as its intrinsic value, is the underlying worth of Pharming Group NV Company, which is reflected in its stock price. It is based on Pharming Group's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Pharming Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Pharming Group NV helps investors to forecast how Pharming pink sheet's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharming Group more accurately as focusing exclusively on Pharming Group's fundamentals will not take into account other important factors: Pharming Group NV Company Current Valuation Analysis
Pharming Group's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Pharming Group Current Valuation | 721.19 M |
Most of Pharming Group's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Pharming Group NV is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Pharming Group NV has a Current Valuation of 721.19 M. This is 94.98% lower than that of the Healthcare sector and 84.48% lower than that of the Biotechnology industry. The current valuation for all United States stocks is 95.66% higher than that of the company.
Pharming Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Pharming Group's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics of similar companies.Pharming Group is currently under evaluation in current valuation category among its peers.
Pharming Fundamentals
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0643 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 721.19 M | |||
| Shares Outstanding | 652.41 M | |||
| Shares Owned By Insiders | 1.97 % | |||
| Shares Owned By Institutions | 16.43 % | |||
| Price To Earning | 18.97 X | |||
| Price To Book | 3.94 X | |||
| Price To Sales | 3.69 X | |||
| Revenue | 167.68 M | |||
| Gross Profit | 177.73 M | |||
| EBITDA | 41.22 M | |||
| Net Income | 16 M | |||
| Cash And Equivalents | 189.96 M | |||
| Cash Per Share | 0.29 X | |||
| Total Debt | 122.65 M | |||
| Debt To Equity | 0.75 % | |||
| Current Ratio | 5.22 X | |||
| Book Value Per Share | 0.30 X | |||
| Cash Flow From Operations | 37.84 M | |||
| Earnings Per Share | 0.05 X | |||
| Target Price | 24.89 | |||
| Number Of Employees | 277 | |||
| Beta | 0.98 | |||
| Market Capitalization | 880.76 M | |||
| Total Asset | 350.55 M | |||
| Retained Earnings | (273 M) | |||
| Working Capital | 23 M | |||
| Current Asset | 41 M | |||
| Current Liabilities | 18 M | |||
| Z Score | 4.2 | |||
| Net Asset | 350.55 M |
About Pharming Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Pharming Group NV's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group NV based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Pharming Pink Sheet
When determining whether Pharming Group NV is a strong investment it is important to analyze Pharming Group's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pharming Group's future performance. For an informed investment choice regarding Pharming Pink Sheet, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.